Creatine Monohydrate ( DrugBank: Creatine )

4 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
2	筋萎縮性側索硬化症	2
8	ハンチントン病	5
113	筋ジストロフィー	2
156	レット症候群	1

2. 筋萎縮性側索硬化症

臨床試験数 : 645 / 薬物数 : 589 - (DrugBank : 163) / 標的遺伝子数 : 150 - 標的パスウェイ数 : 225

diseases per page:

Showing 1 to 2 of 2 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00069186 (ClinicalTrials.gov)	June 2003	17/9/2003	Study of Creatine Monohydrate in Patients With Amyotrophic Lateral Sclerosis	A Phase III, Multi-Center, Double-Blind, Placebo Controlled, Randomized Study of Creatine Monohydrat ...	Amyotrophic Lateral Sclerosis (ALS)	Drug: Creatine Monohydrate	The Avicena Group	NULL	Active, not recruiting	21 Years	80 Years	Both	107	Phase 3	United States
2	NCT00070993 (ClinicalTrials.gov)	December 2002	9/10/2003	Creatine for the Treatment of Amyotrophic Lateral Sclerosis	Clinical Trial of Creatine in Amyotrophic Lateral Sclerosis	Amyotrophic Lateral Sclerosis	Drug: creatine monohydrate	National Center for Complementary and Integrative Health (NCCIH)	Office of Dietary Supplements (ODS)	Completed	21 Years	80 Years	Both	110	Phase 2	United States

First Previous1Next Last

8. ハンチントン病

臨床試験数 : 242 / 薬物数 : 205 - (DrugBank : 62) / 標的遺伝子数 : 85 - 標的パスウェイ数 : 159

diseases per page:

Showing 1 to 5 of 5 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01411163 (ClinicalTrials.gov)	April 2010	4/8/2011	Premanifest Huntington's Disease Extension Study II: Creatine Safety & Tolerability	Premanifest Huntington's Disease Extension Study II: Creatine Safety & Tolerability	Huntington's Disease	Drug: Creatine monohydrate	Massachusetts General Hospital	National Institutes of Health (NIH)	Completed	26 Years	N/A	Both	24	Phase 2	United States
2	NCT00712426 (ClinicalTrials.gov)	September 2009	8/7/2008	Creatine Safety, Tolerability, & Efficacy in Huntington's Disease (CREST-E)	Creatine Safety, Tolerability, & Efficacy in Huntington's Disease (CREST-E)	Huntington's Disease	Drug: Creatine Monohydrate;Drug: Placebo	Massachusetts General Hospital	University of Rochester;National Center for Complementary and Integrative Health (NCCIH)	Terminated	18 Years	N/A	Both	553	Phase 3	United States;Australia;Canada;New Zealand
3	NCT01411150 (ClinicalTrials.gov)	May 2009	4/8/2011	Premanifest Huntington's Disease: Creatine Safety & Tolerability Extension Study	Premanifest Huntington's Disease: Creatine Safety & Tolerability Extension Study	Huntington's Disease	Drug: Creatine Monohydrate	Massachusetts General Hospital	National Institutes of Health (NIH)	Completed	26 Years	N/A	Both	38	Phase 2	United States
4	NCT00592995 (ClinicalTrials.gov)	December 2007	28/12/2007	Creatine Safety and Tolerability in Premanifest HD: PRECREST	Creatine Safety and Tolerability in Premanifest HD: PRECREST	Huntington Disease	Drug: Creatine monohydrate;Drug: Placebo	Massachusetts General Hospital	NULL	Completed	26 Years	N/A	Both	64	Phase 2	United States
5	NCT01412151 (ClinicalTrials.gov)	April 2005	5/8/2011	Creatine Safety & Tolerability in Huntington's Disease	Creatine Safety & Tolerability in Huntington's Disease (CREST-X): A Single-Center, Open-Label, Long- ...	Huntington's Disease (HD)	Drug: Creatine monohydrate	Massachusetts General Hospital	NULL	Completed	18 Years	N/A	All	10	Phase 2	United States

First Previous1Next Last

先頭へ

113. 筋ジストロフィー

臨床試験数 : 646 / 薬物数 : 471 - (DrugBank : 105) / 標的遺伝子数 : 59 - 標的パスウェイ数 : 170

diseases per page:

Showing 1 to 2 of 2 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00018109 (ClinicalTrials.gov)	June 2001	3/7/2001	A Multicenter Randomized Placebo-Controlled Double-Blind Study to Assess Efficacy and Safety of Glut ...	A Multicenter Randomized Placebo-Controlled Double-Blind Study to Assess Efficacy and Safety of Glut ...	Muscular Dystrophy, Duchenne	Drug: glutamine;Drug: creatine monohydrate	National Center for Research Resources (NCRR)	Children's Research Institute	Completed	5 Years	10 Years	Male		Phase 3	United States
2	NCT00016653 (ClinicalTrials.gov)	June 2000	21/5/2001	Creatine and Glutamine in Steroid-Naive Duchenne Muscular Dystrophy	A Multicenter Randomized Placebo-controlled Double-blind Study to Assess Efficacy and Safety of Glut ...	Muscular Dystrophy, Duchenne	Drug: Creatine Monohydrate;Drug: Glutamine	Cooperative International Neuromuscular Research Group	NULL	Completed	5 Years	9 Years	Male	48	Phase 2/Phase 3	United States;Belgium;Israel;Puerto Rico

First Previous1Next Last

156. レット症候群

臨床試験数 : 44 / 薬物数 : 61 - (DrugBank : 23) / 標的遺伝子数 : 57 - 標的パスウェイ数 : 83

diseases per page:

Showing 1 to 1 of 1 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01147575 (ClinicalTrials.gov)	January 2005	17/6/2010	Effects of Creatine Supplementation in Rett Syndrome	Effects of Creatine Supplementation in Rett Syndrome: A Randomized, Placebo-controlled Trial	Rett Syndrome	Dietary Supplement: Creatine monohydrate;Dietary Supplement: Placebo	Medical University of Vienna	NULL	Completed	3 Years	24 Years	Female	21	N/A	Austria

First Previous1Next Last

先頭へ